• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Avalo Therapeutics to Present at Upcoming Investor Conferences

    11/11/24 7:00:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email

    WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences:

    Stifel 2024 Healthcare Conference, New York

    Monday, November 18, 2024 at 3:35 PM ET

    Piper Sandler 36th Annual Healthcare Conference, New York

    Wednesday, December 5, 2024 at 11:00 AM ET

    Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcasts will be available for replay for at least 30 days.

    About Avalo Therapeutics

    Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional drug candidates, which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit www.avalotx.com.

    About AVTX-009 

    AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.

    For media and investor inquiries

    Christopher Sullivan, CFO

    Avalo Therapeutics, Inc.

    [email protected] 

    410-803-6793

    or

    Meru Advisors

    Lauren Glaser

    [email protected] 



    Primary Logo

    Get the next $AVTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTX

    DatePrice TargetRatingAnalyst
    3/25/2025$36.00Buy
    Stifel
    3/25/2025$23.00Buy
    Jefferies
    2/28/2025$48.00Overweight
    Piper Sandler
    2/21/2025$18.00Outperform
    Wedbush
    12/19/2024$40.00Buy
    BTIG Research
    10/24/2024Neutral
    H.C. Wainwright
    4/16/2024$35.00Perform → Outperform
    Oppenheimer
    3/3/2022$5.00 → $0.75Buy → Hold
    Jefferies
    More analyst ratings

    $AVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chan Mitchell converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 8:06:11 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Goldman Jonathan converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:55:44 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Truex Samantha converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:44:14 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/14/24 6:23:00 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

      SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/14/24 12:05:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

      SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/7/24 5:00:07 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      11/14/24 5:21:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    SEC Filings

    See more
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/8/25 7:02:47 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Avalo Therapeutics Inc.

      DEFA14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/1/25 7:02:41 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Avalo Therapeutics Inc.

      DEF 14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/1/25 7:00:42 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

      WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company

      4/30/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports 2024 Financial Results and Recent Business Updates

      Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

      3/20/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Avalo Therapeutics with a new price target

      Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Avalo Therapeutics with a new price target

      Jefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Avalo Therapeutics with a new price target

      Piper Sandler initiated coverage of Avalo Therapeutics with a rating of Overweight and set a new price target of $48.00

      2/28/25 7:19:02 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports 2024 Financial Results and Recent Business Updates

      Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

      3/20/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

      WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. "We are thrilled to welcome Jennifer to Avalo in the newly established role of Chief Strategy Officer," said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. "Jennifer brings extensive leadership

      1/2/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care